STARTech Early Ventures

SensorLogic is a provider of cloud-based, machine-to-machine (M2M) service delivery solutions, specializing in a platform-as-a-service (PaaS) model tailored for M2M applications. The company's offerings include a customizable service delivery platform that features open device and network management, business logic, and complex event processing capabilities. With its XpressIQ Service Suite, SensorLogic enables customers to access ready-to-use applications for GPS tracking, asset monitoring, and control, along with value-added network services. The platform is designed to facilitate the development and deployment of innovative M2M applications, capitalizing on the integration of connected devices within a nationwide GSM/GPRS network.

SensorLogic is a provider of cloud-based, machine-to-machine (M2M) service delivery solutions, specializing in a platform-as-a-service (PaaS) model tailored for M2M applications. The company's offerings include a customizable service delivery platform that features open device and network management, business logic, and complex event processing capabilities. With its XpressIQ Service Suite, SensorLogic enables customers to access ready-to-use applications for GPS tracking, asset monitoring, and control, along with value-added network services. The platform is designed to facilitate the development and deployment of innovative M2M applications, capitalizing on the integration of connected devices within a nationwide GSM/GPRS network.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.

Mirage Networks was a network security company that specialized in providing effective and easily deployable security solutions for enterprises. The company developed a comprehensive network access control platform that allowed users to manage and control network access across various devices, endpoints, and operating systems. To reach its clients, Mirage operated through a global network of resellers, original equipment manufacturers, and managed security service providers, ensuring widespread availability of its innovative security technologies.

Quickshift provides warehousing and e-commerce fulfillment services along with fleet support for distribution. It helps streamline the storage, distribution, and fulfillment across retail, wholesale, and e-commerce channels. The company was founded in 2014 and is headquartered in Pune, Maharashtra, India.

Pintail Technologies, Inc. specializes in real-time adaptive test technology tailored for semiconductor manufacturing. The company provides SwifTest, an online adaptive test module that operates directly on automated test equipment (ATE) to capture and analyze data in real-time. Complementing this is TestScape, an optional database system that receives data from SwifTest and supports various data management applications. Pintail's offerings also include TestScape-Charzilla for device characterization, TestScape-Aware for unified test result dashboards across multiple testers and facilities, and TestScape-OPS for real-time test floor management and overall equipment effectiveness. Additionally, the company offers TestVision for analyzing test data with advanced statistical process control techniques, as well as SwifTest-TTO for real-time statistical sampling to reduce test time and SwifTest-MAX for complex monitoring and analysis. Pintail Technologies serves a diverse clientele including integrated device manufacturers, fabless companies, and automated test equipment manufacturers, with products available in the United States, Japan, and various regions in Asia and Europe. The company has established strategic alliances with Teradyne Inc. and Salland Engineering.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.

Voyence provides configuration and change management solutions that automate critical change, compliance, and activation processes. The company offers VoyenceControl NG solution, which manages various devices in a heterogeneous infrastructure; automates configuration management lifecycle, including design, change, and compliance; and collects data in its repository, including configuration, asset/hardware, and change and audit information. It offers compliance/security, change/configuration, and extending network management solutions. The company's customers include financial, healthcare, education, government, manufacturing, services, technology, and transportation organizations. Voyence, Inc. was founded in 2000 as PowerUp Networks and it changed its name to Voyence, Inc. in 2003. The company is headquartered in Richardson, Texas.

Metreos Corporation, founded in 2001 by Louis Marascio and Mark Richards, specializes in providing an IP telephony development and run-time platform that enables companies to build, deploy, and manage IP telephony applications. The company offers both packaged applications and a comprehensive set of tools for customizing and managing these applications within IP telephony networks. Metreos primarily serves large enterprises that have transitioned from traditional TDM phone systems to Voice-over-IP systems, particularly those utilizing Cisco Systems as their VoIP provider. Since 2004, notable clients such as Lehman Brothers and BearingPoint have utilized Metreos products to tailor their IP telephony solutions, compensating for features that were not carried over from their previous systems. In recognition of the value provided to its large enterprise customers, Cisco acquired Metreos in June 2006 for $28 million, further integrating its capabilities into Cisco's offerings.

AppTrigger, Inc. provides telecommunications application connectivity solutions. It offers Application Session Controller software, a network element that sits between the application cloud and the converging network/control layer to provide and manage connectivity to the evolving network for multiple applications. The company also provides support programs, and professional and training services. AppTrigger, Inc. was formerly known as Carrius Technologies, Inc. The company was founded in 2002 and is based in Richardson, Texas.

Metreos Corporation, founded in 2001 by Louis Marascio and Mark Richards, specializes in providing an IP telephony development and run-time platform that enables companies to build, deploy, and manage IP telephony applications. The company offers both packaged applications and a comprehensive set of tools for customizing and managing these applications within IP telephony networks. Metreos primarily serves large enterprises that have transitioned from traditional TDM phone systems to Voice-over-IP systems, particularly those utilizing Cisco Systems as their VoIP provider. Since 2004, notable clients such as Lehman Brothers and BearingPoint have utilized Metreos products to tailor their IP telephony solutions, compensating for features that were not carried over from their previous systems. In recognition of the value provided to its large enterprise customers, Cisco acquired Metreos in June 2006 for $28 million, further integrating its capabilities into Cisco's offerings.

AppTrigger, Inc. provides telecommunications application connectivity solutions. It offers Application Session Controller software, a network element that sits between the application cloud and the converging network/control layer to provide and manage connectivity to the evolving network for multiple applications. The company also provides support programs, and professional and training services. AppTrigger, Inc. was formerly known as Carrius Technologies, Inc. The company was founded in 2002 and is based in Richardson, Texas.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

OraMetrix, Inc. provides 3-D technology solutions for facilitating and improving the quality of orthodontic care. It offers an orthodontic treatment system that allows the use of precision digital tools throughout the diagnosis, treatment planning and monitoring, and arch wire customization processes of the orthodontic treatment. OraMetrix, Inc. was formerly known as Orthotel, Inc. The company was founded in 1998 and is based in Richardson, Texas with an additional office in Berlin, Germany.